Benzinga | Aug 13, 2020 08:17AM EDT

Alimera Sciences Reports Distribution Deal With Nordic Prime To Expand Int'l. Sales OF ILUVIEN Into Nordic Countries

Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, today announced that its Ireland-based European subsidiary, Alimera Sciences Europe Limited, has signed a distribution agreement with Nordic Prime ApS to serve as Alimera's distribution partner in Denmark, Finland, Norway and Sweden for ILUVIEN(r) 190 micrograms intravitreal implant in applicator. ILUVIEN is approved in these territories for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies and for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.

Under the Agreement, Nordic Prime will engage in hospital tendering activities to secure purchasing agreements of ILUVIEN across the Nordic region and is responsible for shipping of orders and maintaining all back-office support for Nordic customers.

"We continue to advance our strategy of geographically expanding the availability of ILUVIEN into additional countries to increase our global market share and sales," said Rick Eiswirth, President and Chief Executive Officer of Alimera. "Working with Nordic Prime enables us to supply ILUVIEN to hospitals and physicians in the Nordic region of Europe, where more than 100,000 patients are estimated to suffer from either diabetic macular edema or non-infectious posterior uveitis."

"We are extremely pleased to be a part of Alimera's strategic commercial expansion in the Nordic European countries," said Patricio Aguirre, Managing Director of Nordic Prime. "We believe ILUVIEN's ability to control the recurrence of debilitating retinal diseases and improve patients' vision with fewer injections, will provide significant benefits to Nordic physicians and their patients."